Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cortexyme Inc (CRTX)

Cortexyme Inc (CRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 666,466
  • Shares Outstanding, K 26,852
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,480 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.87

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.39
  • Number of Estimates 1
  • High Estimate -0.39
  • Low Estimate -0.39
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
20.14 +27.16%
on 11/05/19
29.23 -12.38%
on 11/18/19
+3.85 (+17.69%)
since 10/18/19
3-Month
19.35 +32.35%
on 08/30/19
29.99 -14.60%
on 09/13/19
+0.35 (+1.39%)
since 08/20/19

Most Recent Stories

More News
Cortexyme Announces Third Quarter 2019 Financial Results and Provides Business Update

---- Following successful May 2019 initial public offering, Cortexyme is well capitalized and focused on high quality execution of the GAIN Trial

CRTX : 25.61 (+3.18%)
The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

CRTX : 25.61 (+3.18%)
ZM : 70.99 (+1.94%)
BYND : 78.12 (+1.00%)
TPTX : 52.13 (+2.62%)
4 Best-Performing IPOs So Far in 2019

Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.

AMZN : 1,745.53 (-0.41%)
FB : 197.51 (-0.91%)
CRTX : 25.61 (+3.18%)
TPTX : 52.13 (+2.62%)
BYND : 78.12 (+1.00%)
LYFT : 43.95 (-0.45%)
UBER : 28.03 (+3.62%)
PINS : 19.40 (-1.42%)
ZM : 70.99 (+1.94%)
WORK : 21.70 (+2.46%)
Cortexyme Announces Oral Presentation on COR388 at Clinical Trials on Alzheimer's Disease 2019

--- CTAD attendees are also invited to educational session focused on Cortexyme's new investigational approach to AD treatment

CRTX : 25.61 (+3.18%)
Top Ranked Momentum Stocks to Buy for September 30th

Top Ranked Momentum Stocks to Buy for September 30th

SOL : 1.50 (+4.17%)
ROCK : 52.27 (-0.48%)
DAC : 9.33 (-7.82%)
CRTX : 25.61 (+3.18%)
Cortexyme Announces European Screening Now Underway in the Phase 2/3 GAIN Trial

--- GAIN Trial opened for U.S. enrollment in Q2 2019 and is expected to include approximately 90 sites globally

CRTX : 25.61 (+3.18%)
Top Ranked Momentum Stocks to Buy for September 23rd

Top Ranked Momentum Stocks to Buy for September 23rd

ROAD : 18.65 (+0.48%)
RLGT : 5.05 (-1.94%)
CRTX : 25.61 (+3.18%)
BLCM : 0.83 (-4.31%)
Cortexyme to Present at the Canaccord Genuity Growth Conference on August 7th

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's and other degenerative...

CRTX : 25.61 (+3.18%)
Cortexyme's Approach to Addressing a Key Underlying Cause of Alzheimer's Detailed at Alzheimer's Association International Conference 2019

-- In Phase 1b testing, COR388 was associated with reductions in markers of inflammation and pathological ApoE fragmentation

CRTX : 25.61 (+3.18%)
Cortexyme Announces Upcoming Data Presentations at the Alzheimer's Association International Conference 2019

Cortexyme, Inc. (Nasdaq: CRTX), today announced that its work to pioneer a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer's and other degenerative diseases will...

CRTX : 25.61 (+3.18%)
Trade CRTX with:

Business Summary

Cortexyme Inc. is a clinical-stage biopharmaceutical company. It is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The company's drug candidate consists of COR388 which is in clinical stage. Cortexyme Inc. is based in San Francisco, United States....

See More

Key Turning Points

2nd Resistance Point 28.68
1st Resistance Point 27.15
Last Price 25.61
1st Support Level 24.69
2nd Support Level 23.76

See More

52-Week High 47.50
Fibonacci 61.8% 36.75
Fibonacci 50% 33.42
Fibonacci 38.2% 30.10
Last Price 25.61
52-Week Low 19.35

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar